Hangzhou JiaLiang Brain Science Co., Ltd. has proudly declared the successful conclusion of its Series C and Series D funding rounds, amassing a substantial sum totaling several hundred million yuan. This influx of capital comes from a diverse array of investors, encompassing both market-oriented venture capital/private equity firms and esteemed state-owned institutions. Established in 2020 by Cao Peng, a distinguished alumnus of Xi'an Jiaotong University, the company strategically operates through dual hubs in Hangzhou and Singapore. It boasts a well-rounded product portfolio that spans the precise diagnosis and treatment of brain ailments, closed-loop neural modulation, and the management of brain health.

At present, JiaLiang Brain Science has secured four Class III medical device registration certificates from the national authorities, with several of its core products already making their way into clinical practice. The company has engineered a trinity technological framework, seamlessly integrating 'smart hardware + multimodal data + AI large models.' This framework is underpinned by two proprietary technological platforms. Moreover, JiaLiang Brain Science has forged clinical partnerships with over 50 premier hospitals nationwide.

In the realm of intellectual property, the company's prowess is evident with over 400 patents filed, of which more than 190 have been granted. Presently, the brain-computer interface industry stands at a pivotal juncture, transitioning from technological exploration to clinical translation and industrialization. JiaLiang Brain Science is at the forefront, vigorously driving the commercialization and internationalization of its offerings. Its synergy of brain-computer interfaces with AI technology is pushing the envelope, broadening the horizons of technological applications.